Urolithin A, a novel natural compound to target PI3K/AKT/mTOR pathway in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy and is highly resistant to standard treatment regimens. Targeted therapies against KRAS, a mutation present in an overwhelming majority of PDAC cases, have been largely ineffective. However, inhibition of downstream components in th...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Cancer Ther
Autori principali: Totiger, Tulasigeri M., Srinivasan, Supriya, Jala, Venkatakrishna R., Lamichhane, Purushottam, Dosch, Austin R., Gaidarski, Alexander A., Joshi, Chandrashekhar, Rangappa, Shobith, Castellanos, Jason, Vemula, Praveen Kumar, Chen, Xi, Kwon, Deukwoo, Kashikar, Nilesh, VanSaun, Michael, Merchant, Nipun B., Nagathihalli, Nagaraj S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6363854/
https://ncbi.nlm.nih.gov/pubmed/30404927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-0464
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi